Company profile

Shanghai Simnova Biotechnology Co., Ltd.

Privately held: no public share price (Privately-held Shanghai/Boston clinical-stage cell-therapy biotech (CAR-T/CAR-NK), sister company of HKEX-listed Simcere Pharmaceutical Group but itself not separately listed; raised CNY 200M Series A+ (prnewswire, cbinsights). No independent public listing found. Sources: https://clinicaltrials.gov/study/NCT05346198 Entity resolved by asset-pipeline-v2.)

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1
BCMACell therapy
Multiple Myeloma
Phase 1
Undisclosed / early pipelineCell therapy
Systemic Lupus Erythematosus

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.